Try our beta test site
10 studies found for:    cerulean
Show Display Options
Rank Status Study
1 Active, not recruiting CRLX101 Plus Bevacizumab in Advanced RCC
Condition: Renal Cell Carcinoma
Interventions: Drug: CRLX101 (Cerulean);   Drug: Bevacizumab
2 Completed A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CRLX101;   Other: Best Supportive Care
3 Recruiting Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: CRLX101;   Drug: Bevacizumab;   Drug: mFOLFOX6
4 Active, not recruiting CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: CRLX101 + bevacizumab;   Drug: sorafenib / everolimus / pazopanib / axitinib / bevacizumab / sunitinib / other approved drug
5 Active, not recruiting A Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Condition: Ovarian Cancer
Intervention: Drug: CRLX101 and weekly paclitaxel
6 Active, not recruiting Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumor Malignancy
Intervention: Drug: CRLX301
7 Withdrawn Efficacy Study of Maintenance Therapy for Ovarian Cancer Patients
Conditions: Cancer;   Ovarian Cancer;   Solid Tumor
Interventions: Drug: IT-101;   Drug: 5% Dextrose (Placebo)
8 Terminated Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
Conditions: Cancer;   Ovarian Cancer;   Solid Tumor
Interventions: Drug: IT-101 (12mg/m2/dose);   Drug: IT-101 (15mg/m2/dose);   Drug: 5% Dextrose (Placebo)
9 Completed Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Conditions: Cancer;   Solid Tumor
Intervention: Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
10 Active, not recruiting Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
Condition: Rectal Cancer
Interventions: Drug: CRLX101;   Drug: Capecitabine;   Radiation: Radiotherapy;   Procedure: Surgery

Study has passed its completion date and status has not been verified in more than two years.